Insmed (INSM) falls 18% premarket after reporting the results of a Phase 3 trial for Arikace....

|By:, SA News Editor

Insmed (INSM) falls 18% premarket after reporting the results of a Phase 3 trial for Arikace. Although the treatment achieved the primary non-inferiority endpoint, it appears Arikace did not show as well as tobramycin inhalation solution in terms of FEV1 (see presentation, slide 3).